Abstract
Latest World Health Organization guidelines recommend weight-based nevirapine prophylaxis for all HIV-exposed infants in resource-limited settings, yet low birth weight (LBW) infants (< 2500 g) have been understudied. Using data from the NIH-funded India six-week extended-dose nevirapine (SWEN) study, a randomized clinical trial of SWEN versus single-dose nevirapine (SD) for prevention of breast-milk HIV-1 transmission, we examined the relative impact of SWEN among 737 mother-infant pairs stratified by infant birth weight. Birth weight groups were defined as very LBW (VLBW) ≤ 2000 g, moderate LBW (MLBW) >2000 g and ≤ 2500 g, and normal birth weight (NBW) > 2500 g. Outcomes were HIV-1 infection, HIV-1 infection or death by 12 months, and severe adverse events (SAEs). The Kaplan-Meier method was used to estimate probability of efficacy outcomes in birth weight groups, and differential effects of SWEN by birth weight group were examined using Cox proportional hazards models adjusting for independent risk factors for HIV maternal-to-child transmission and significant covariates. Among 50 VLBW, 249 MLBW, and 433 NBW infants, 50% were randomized to SWEN; median gestational age was 36, 38 and 38 weeks, respectively; and there was no difference in breastfeeding duration (p = 0.99). Compared to SD: SWEN-treated VLBW had lower estimates of HIV-1 infection (13% vs. 38%, p = 0.004) and HIV-1 infection or death (13% vs. 41%, p = 0.002); SWEN-treated MLBW had lower estimated HIV-1 infection (13% vs. 17%, p = 0.042); and efficacy endpoints were similar by treatment arm in NBW. In multivariate analysis, SWEN was associated with reduced risk of HIV-1 infection or death by 83% (p = 0.03) in VLBW versus 45% (p = 0.05) in MLBW. SAE frequency was similar by treatment arm in VLBW (68% vs. 76%, p = 0.53) and MLBW (37% vs. 36%, p = 0.93). SWEN may safely increase HIV-free survival among HIV-exposed LBW infants with greatest protective advantage among infants ≤ 2000 g.
Highlights
Low birth weight (LBW), defined by the World Health Organization (WHO) as birth weight less than 2500 g, is a significant public health issue in resource-limited settings, in Sub Saharan Africa and South Asia where the estimated annual incidence is 14% and 28–31%, respectively, and the HIV burden among women of reproductive age is high [1,2]
Birth weight groups were similar among breastfeeding duration, proportion of infants randomized to six-week extended-dose nevirapine (SWEN), median maternal age, maternal use of highly active antiretroviral therapy, and median maternal CD4 count at delivery (Table 1)
very LBW (VLBW) had lower maternal antepartum zidovudine use compared to moderate LBW (MLBW) (8% vs. 31%, p = 0.001) and the lowest proportion of mothers who received intrapartum nevirapine relative to MLBW and normal birth weight (NBW) (30% vs. 61% vs. 73%, p
Summary
Low birth weight (LBW), defined by the World Health Organization (WHO) as birth weight less than 2500 g, is a significant public health issue in resource-limited settings, in Sub Saharan Africa and South Asia where the estimated annual incidence is 14% and 28–31%, respectively, and the HIV burden among women of reproductive age is high [1,2]. Safety and efficacy data in LBW infants are limited as most studies have either excluded or enrolled LBW infants in small numbers [6,11,15,16,17,18,19,20]. Based on their relative physiologic immaturity, LBW infants may metabolize and respond differently to nevirapine than normal birth weight infants. The impact of extended nevirapine prophylaxis may vary by infant birth weight and optimal dosing may not be known
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
